COLL · Insider Trading
Collegium Pharmaceutical, Inc. Common Stock
Every open-market purchase and sale reported by COLL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-10 | Gino Santini | Director | M | +8,700 | +$143.46K |
| 2026-05-20 | John Gordon Freund | Director | Sell | −20 | −$681 |
| 2026-05-18 | Garen G Bohlin | Director | A | +8,741 | — |
| 2026-05-18 | Carlos V Paya | Director | A | +8,741 | — |
| 2026-05-18 | Donovan Michael Glancy | Director | A | +17,482 | — |
| 2026-05-18 | Gino Santini | Director | A | +8,741 | — |
| 2026-05-18 | Rita J. Balice-Gordon | Director | A | +8,741 | — |
| 2026-05-18 | Nancy Lurker | Director | A | +8,741 | — |
| 2026-05-18 | John Gordon Freund | Director | MIXED | +13,314 | +$916 |
| 2026-05-15 | Nancy Lurker | Director | Sell | −4,500 | −$161.86K |
| 2026-05-13 | Garen G Bohlin | Director | MIXED | — | −$180.03K |
| 2026-04-03 | David Dieter | EVP & General Counsel | F | −8,840 | −$315.76K |
| 2026-03-20 | David Dieter | EVP & General Counsel | Sell | −13,976 | −$488.10K |
| 2026-03-11 | David Dieter | EVP & General Counsel | Sell | −6,224 | −$228.11K |
| 2026-03-05 | Scott Dreyer | EVP & Chief Commercial Officer | Sell | −49,976 | −$2.02M |
| 2026-02-12 | Thomas B Smith | EVP and Chief Medical Officer | MIXED | +19,607 | −$815.09K |
| 2026-02-12 | Vikram Karnani | President and CEO | MIXED | +100,499 | −$528.09K |
| 2026-02-12 | Scott Dreyer | EVP & Chief Commercial Officer | MIXED | +18,133 | −$1.48M |
| 2026-02-12 | David Dieter | EVP & General Counsel | MIXED | +28,418 | −$130.01K |
| 2026-02-12 | Colleen Tupper | EVP & Chief Financial Officer | MIXED | +20,615 | −$1.80M |
| 2025-12-10 | Scott Dreyer | EVP & Chief Commercial Officer | MIXED | — | −$568.02K |
| 2025-12-09 | Rita J. Balice-Gordon | Director | Sell | −3,650 | −$171.67K |
| 2025-11-14 | Vikram Karnani | President and CEO | F | −8,983 | −$425.35K |
| 2025-11-14 | John A. Fallon | Director | MIXED | — | −$1.21M |
| 2025-11-07 | Colleen Tupper | EVP & Chief Financial Officer | Sell | −30,000 | −$1.22M |
| 2025-09-03 | Thomas B Smith | EVP and Chief Medical Officer | Sell | −17,478 | −$671.58K |
| 2025-08-20 | Scott Dreyer | EVP & Chief Commercial Officer | MIXED | — | −$276.43K |
| 2025-08-19 | Gino Santini | Director | MIXED | +9,595 | +$732 |
| 2025-08-15 | Rubric Capital Management LP | 10%+ Owner | Sell | −25,000 | −$946.25K |
| 2025-08-15 | Scott Dreyer | EVP & Chief Commercial Officer | MIXED | — | −$81.15K |
| 2025-08-12 | John Gordon Freund | Director | Sell | −11,659 | −$400.64K |
| 2025-06-11 | John Gordon Freund | Director | MIXED | +8,399 | −$399 |
| 2025-05-19 | Carlos V Paya | Director | A | +19,582 | — |
| 2025-05-19 | John A. Fallon | Director | A | +9,791 | — |
| 2025-05-19 | Gino Santini | Director | A | +9,791 | — |
| 2025-05-19 | Nancy Lurker | Director | A | +9,791 | — |
| 2025-05-19 | Rita J. Balice-Gordon | Director | A | +9,791 | — |
| 2025-05-19 | John Gordon Freund | Director | A | +9,791 | — |
| 2025-05-19 | Garen G Bohlin | Director | A | +9,791 | — |
| 2025-03-24 | Colleen Tupper | EVP & Chief Financial Officer | Sell | −7,602 | −$228.25K |
| 2025-03-24 | Scott Dreyer | EVP & Chief Commercial Officer | Sell | −20,808 | −$624.79K |
| 2025-03-19 | David Dieter | EVP & General Counsel | A | +68,449 | — |
| 2025-03-18 | Scott Dreyer | EVP & Chief Commercial Officer | Sell | −2,255 | −$67.66K |
| 2025-03-18 | Scott Dreyer | EVP & Chief Commercial Officer | Sell | −15,387 | −$461.67K |
| 2025-03-18 | Colleen Tupper | EVP & Chief Financial Officer | Sell | −977 | −$29.31K |
| 2025-03-13 | Scott Dreyer | EVP & Chief Commercial Officer | Sell | −15,387 | −$461.67K |
| 2025-03-13 | Colleen Tupper | EVP & Chief Financial Officer | Sell | −10,445 | −$313.41K |
| 2025-03-10 | Scott Dreyer | EVP & Chief Commercial Officer | Sell | −5,643 | −$169.30K |
| 2025-03-10 | Colleen Tupper | EVP & Chief Financial Officer | Sell | −3,453 | −$103.59K |
| 2025-03-06 | Shirley R. Kuhlmann | EVP and General Counsel | MIXED | −46,067 | −$1.47M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Rubric Capital Management LP | 10%+ Owner | 3,132,743 | $78.02M |
| Michael Thomas Heffernan | Director | 213,371 | $5.31M |
| Vikram Karnani | President and CEO | 209,160 | $5.21M |
| Colleen Tupper | EVP & Chief Financial Officer | 185,822 | $4.63M |
| Shirley R. Kuhlmann | EVP and General Counsel | 134,204 | $3.34M |
| Gino Santini | Director | 112,483 | $2.80M |
| John Gordon Freund | Director | 107,081 | $2.67M |
| John A. Fallon | Director | 99,487 | $2.48M |
| Thomas B Smith | EVP and Chief Medical Officer | 90,651 | $2.26M |
| Scott Dreyer | EVP & Chief Commercial Officer | 75,329 | $1.88M |
| Garen G Bohlin | Director | 71,000 | $1.77M |
| David Dieter | EVP & General Counsel | 68,231 | $1.70M |
| Rita J. Balice-Gordon | Director | 61,370 | $1.53M |
| Carlos V Paya | Director | 28,323 | $705.38K |
| Nancy Lurker | Director | 26,758 | $666.41K |
| Donovan Michael Glancy | Director | 17,482 | $435.39K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the COLL quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.